Comparing a new erythropoietin to Eprex for healthy volunteers
This study tests a new erythropoietin (a medicine that helps your body make red blood cells) and compares it to an approved version called Eprex. It is for healthy adults to see how the two medicines work in the body and if they are safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your body mass index (BMI) must be between 18 and 30.
- You must be a non-smoker or a light smoker (fewer than 10 cigarettes a day) or have quit smoking for at least 3 months.
- You must not have any serious health problems or take certain medicines.
- You must agree to use birth control (if you are a woman who can have children) or be past menopause or surgically sterile.
- You cannot have used erythropoietin before or have donated blood recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests how an injected “copy” version of erythropoietin behaves in the blood in healthy volunteers. It’s mainly about measuring safety and blood-level changes, not treating an illness.
This study tests a new experimental drug called NANOKINE alongside an approved drug (Eprex) to see how your body handles them. It is for healthy male volunteers and will help researchers understand how the new drug works and if it is safe.
This trial tests two similar medicines that help your body make red blood cells. It is for people with advanced chronic kidney disease who are on dialysis, and aims to see if the study medicine works as well as the standard one.
This study tests two medicines (daprodustat and epoetin alfa) to see which one works better for treating low red blood cell counts (anemia) in people with chronic kidney disease who are not on dialysis yet. Both medicines aim to increase hemoglobin and reduce fatigue.
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
This trial tests a new drug called elritercept against a standard treatment, epoetin alfa, for people with a low-risk form of MDS who need regular blood transfusions for anemia. The goal is to see if elritercept works better to reduce the need for transfusions.
Hear when a new Healthy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.